Wikipedia

Michelle Haber

Michelle Haber AM FAA FAHMS is an Australian cancer researcher in the field of childhood cancer research.

Michelle Haber
Born
Liverpool, England
NationalityAustralian
Alma materUniversity of New South Wales
Known forIdentifying molecular targets in neuroblastoma and developing novel therapeutic approaches against them
AwardsDoctor of Science honoris causa, UNSW (2008)
Scientific career
FieldsPaediatric cancer
Institutions

Early life and education edit

Michelle Haber was born in Liverpool, England.[citation needed]

Haber attended Mount Scopus Memorial College in Melbourne and, when her family moved to Sydney, attended Moriah College, graduating in 1973.[citation needed]

She completed a clinical psychology degree at University of New South Wales and was awarded a University Medal. She obtained her PhD from the School of Pathology at the University of New South Wales in 1984 - her thesis was entitled "Structural analysis by BD-cellulose chromatography of mammalian DNA during repair, replication and degradation".[1]

Career edit

In 1982, during her PhD studies, Haber spent three months as Visiting Research Fellow at the Department of Molecular Virology in Hadassah Medical Centre, Hebrew University of Jerusalem. Her first postdoctoral position was as at Children’s Leukaemia and Cancer Research Unit, a precursor to Children's Cancer Institute then located at the Prince of Wales Children’s Hospital, Randwick. Having joined as a Staff Scientist in 1984,[2] she was promoted to Senior Research Fellow in 1992, Principal Research Fellow in 1996, Director in 2000[2] and Executive Director in 2003.[2] Haber also holds a conjoint appointment as Professor in the Faculty of Medicine at the University of New South Wales.[3]

She serves as the executive director of Children's Cancer Institute[4] and is a professor at the School of Women’s and Children’s Health, University of New South Wales.[5] She is known for her discoveries in the area of chemotherapy resistance in neuroblastoma and for translating these discoveries into new therapeutics that are currently in clinical trials.[6]

Under her leadership Children's Cancer Institute, now located in the UNSW Lowy Cancer Research Centre,[7] has tripled in size and grown from a little known group to become the largest children’s cancer research facility in the region.[8]

Research edit

Haber’s early studies were amongst the first characterising the complex molecular mechanisms underlying therapy-related drug resistance.[9][10] With her collaborators, she identified the relationship between high expression of multidrug transporter gene MRP1, and the malignant phenotype of neuroblastoma and poor clinical outcome.[11][12] These studies provided the first definitive demonstration of clinical relevance of the MRP1 gene in solid tumours, resulting in a large international clinical study which confirmed the independent prognostic significance of MRP1 expression in neuroblastoma and established MRP1 inhibition as a potential new treatment for this disease.[13]

By high-throughput chemical screening of small molecule libraries, Haber and her colleagues have also developed novel MRP1 inhibitors and patented and licensed the compounds for the treatment of neuroblastoma and other MRP1-associated malignancies. This led to a $3.1M award from the Australian Cancer Research Foundation to establish a Drug Discovery Centre for Childhood Cancer in the UNSW Lowy Cancer Research Centre, which is currently developing a pipeline of potential new drugs for treating childhood and adult malignancies.

Haber and her collaborators have also identified the role of ATP-binding cassette transporter genes (ABC transporters) in neuroblastoma biology, demonstrating that their expression predicts for poor clinical outcome in neuroblastoma[14] but, unexpectedly, this phenomenon was not due to the ABC proteins’ role in drug transport, but through an independent pathway that influences fundamental aspects of tumour biology. A further study on ovarian cancer and ABCA1[15] has extended the discovery to common adult cancers.

Service to the scientific community edit

Haber is[when?] a long-term member of the International Neuroblastoma Risk Group Committee, which makes recommendations regarding standardised protocols and best practice for identifying/utilising prognostic indicators for neuroblastoma treatment risk assessment.[16]

From 2006 to 2014, Haber has served on the steering committee of the Advances in Neuroblastoma Research Association (ANRA), the peak international body for neuroblastoma research[17] and was president of this organisation from 2010 to 2012.

In 2011, Haber also played a key role in establishment of the Kids Cancer Alliance and currently serves on this organization's executive management committee.[18]

Haber is convenor of the 2016 Advances in Neuroblastoma Research conference in Cairns, one of the largest specialist childhood cancer conferences internationally.[19]

Recognition and awards edit

References edit

  1. ^ Haber, Michelle (1984). Structural Analysis by BD-cellulose Chromatography of Mammalian DNA During Repair, Replication and Degradation (Thesis). UNSW Sydney. Retrieved 26 June 2017.
  2. ^ a b c "Paediatrio - Professor Michelle Haber AM BSc (Psych) (Hons), PhD, Hon DSc (UNSW) FAHMS". Retrieved 19 September 2017.
  3. ^ "School of Women's and Children's Health - Professor Michelle Haber". Retrieved 19 September 2017.
  4. ^ "Children's Cancer Institute | Curing Children's Cancer". Ccia.org.au. 3 May 2015. Retrieved 30 June 2017.
  5. ^ "Professor Michelle Haber | Medicine". Med.unsw.edu.au. Retrieved 30 June 2017.
  6. ^ "Professor Glenn Marshall | National Health and Medical Research Council". Archived from the original on 11 September 2014. Retrieved 14 August 2014.
  7. ^ "Welcome - Lowy Cancer Research Centre". lowycancerresearchcentre.unsw.edu.au. Retrieved 26 June 2017.
  8. ^ "Our story - Children's Cancer Institute". ccia.org.au. 3 May 2015. Retrieved 30 June 2017.
  9. ^ Haber, M.; Reed, C.; Kavallaris, M.; Norris, M. D.; Stewart, B. W. (1989). "Resistance to Drugs Associated with the Multidrug Resistance Phenotype Following Selection with High-Concentration Methotrexate". JNCI Journal of the National Cancer Institute. 81 (16): 1250–1254. doi:10.1093/jnci/81.16.1250. PMID 2754745.
  10. ^ Stewart, Bernard W.; White, Les; Davey, Ross A.; Bell, David R.; Kavallaris, Maria; Norris, Murray D.; Haber, Michelle (October 1989). "Atypical Multidrug Resistance in a Therapy-induced Drug-resistant Human Leukemia Cell Line (LALW-2): Resistance to Vinca Alkaloids Independent of P-Glycoprotein". Cancer Research. 49 (19): 5281–5287. PMID 2569932.
  11. ^ Bordow, S. B.; Haber, M.; Madafiglio, J.; Cheung, B.; Marshall, G. M.; Norris, M. D. (1994). "Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma". Cancer Research. 54 (19): 5036–40. PMID 7923112.
  12. ^ Norris, Murray D.; Bordow, Sharon B.; Marshall, Glenn M.; Haber, Paul S.; Cohn, Susan L.; Haber, Michelle (1996). "Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma". New England Journal of Medicine. 334 (4): 231–238. doi:10.1056/nejm199601253340405. PMID 8532000.
  13. ^ Haber, Michelle; Smith, Janice; Bordow, Sharon B.; Flemming, Claudia; Cohn, Susan L.; London, Wendy B.; Marshall, Glenn M.; Norris, Murray D. (2006). "Association of High-LevelMRP1Expression with Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma". Journal of Clinical Oncology. 24 (10): 1546–1553. doi:10.1200/JCO.2005.01.6196. PMID 16575006.
  14. ^ Henderson, M. J.; Haber, M.; Porro, A.; et al. (2011). "ABCC multi drug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux". Journal of the National Cancer Institute. 103 (16): 1236–51. doi:10.1093/jnci/djr256. PMC 3156802. PMID 21799180.
  15. ^ Hedditch, E. L.; et al. (2014). "ABCA transporter gene expression is associated with poor outcome in epithelial ovarian cancer". Journal of the National Cancer Institute. 106 (7): dju149. doi:10.1093/jnci/dju149. PMC 4110473. PMID 24957074.
  16. ^ "Leadership - International Neuroblastoma Risk Group Task Force". inrgdb.org. Retrieved 26 June 2017.
  17. ^ "Advances in Neuroblastoma Research Association Meetings". Anrmeeting.org. Retrieved 26 June 2017.
  18. ^ "Home". Kids Cancer Alliance. Retrieved 30 June 2017.
  19. ^ "Home » ANR 2016". anr2016.org. Retrieved 26 June 2017.
  20. ^ "It's an Honour - Honours - Search Australian Honours". Itsanhonour.gov.au. Retrieved 26 June 2017.
  21. ^ "Scientist of the Year". Newsroom.unsw.edu.au. 24 November 2011. Retrieved 26 June 2017.
  22. ^ "Michelle Haber AM". Australianofotheyear.org.au. Archived from the original on 9 February 2022. Retrieved 9 February 2022.
  23. ^ "NSW Premier's Awards for Outstanding Cancer Research - Cancer Institute NSW". Cancerinstitute.org.au. 7 September 2016. Retrieved 30 June 2017.
  24. ^ "Ten of the Best 2012 | National Health and Medical Research Council". Archived from the original on 12 February 2014. Retrieved 14 August 2014.
  25. ^ Kirby, Tony (2013). "Profile: CCIA—teaming up to target paediatric cancer". The Lancet. 381 (9880): 1804. doi:10.1016/S0140-6736(13)61107-1. PMID 23717834. S2CID 35893252.
  26. ^ "2013 Finalists (Eureka Prizes) - Australian Museum". australianmuseum.net.au. Retrieved 26 June 2017.
  27. ^ "2014 NSW Outstanding Cancer Researcher of the Year Announced - Cancer Institute NSW". Cancerinstitute.org.au. 22 August 2014. Retrieved 30 June 2017.
  28. ^ "Fellowship - AAHMS – Australian Academy of Health and Medical Sciences". Aahms.org. Retrieved 26 June 2017.
  29. ^ "Academy announces 2022 Fellows for outstanding contributions to science". Australian Academy of Science. 26 May 2022. Retrieved 25 May 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michelle_Haber&oldid=1218373196"